Companies · Biotechnology

Magnesium Development Company, LLC

HOLLAND · Biotechnology

Diligence memoA one-page analyst read on Magnesium Development Company, LLC — recommendation, valuation, rhythm, risks.
$2.5M
Total raised · real
1
Rounds
0.7×
Latest step-up
Top 70%
Sector rank · raised
Seed
Latest stage · inferred · Fri Sep 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Magnesium Development Company, LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.53× the median modeled value of Seed Biotechnology companies in 2016–2018 (175 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.8 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Magnesium Development Company, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
10.4 yr record
Peak capital year was 2017 with $4.3M across 2 filings.
Market position
ahead of 31% of Biotechnology peers
Capital scale is ahead of 31% of Biotechnology peers; modeled value is above 60% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $4.3M across 2 filings.
  • Largest single filing was $2.5M on 2017-09-08.
  • Filing rows sum to $5.3M, while canonical raised total is $2.5M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Magnesium Development Company, LLC is one of 4293 Biotechnology companies tracked from HOLLAND. By capital raised it ranks in the long tail (ahead of 31% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
5
Investors (latest)
2014
Year incorporated
2017-09-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2016-02-01 Raised $1.0M (real) Modeled valuation $55M (est)$1.0M$55MPre-Seed2016Seed · 2017-09-08 Raised $2.5M (real) Modeled valuation $109M (est)$2.5M$109MSeed2017Seed · 2017-09-08 Raised $1.8M (real) Modeled valuation $80M (est)$1.8M$80MSeed2017+$2.5M+$1.8MCumulative $5.3M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$1.0M · 2016
Seed$2.5M · 2017
Seed extension$1.8M · 2017

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$108.8M
Base estimate est.
$1.8M
Conservative case
$853.5M
Upside case
$12.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $55.2M · 2016-02-012016Seed · modeled $108.8M · 2017-09-08Seed · modeled $79.9M · 2017-09-082017
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
6.0 yr
Elapsed time used
8.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$1.5M/yr
Capital velocity
10.4 yr
On record since
2016
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.5M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.0× above median
This company$1.8M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.7× above median
This company$108.8M
Sector median$64.2M

Raised more than 31% of sector peers (real $). Modeled value above 60% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #42 of 175.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0MCapital raised (log)Mimedx Group, Inc. · Seed Raised $8.2M · modeled $177.6M (est)Kenjockety Biotechnology, LLC · Seed Raised $4.0M · modeled $177.6M (est)Helocyte, Inc. · Seed Raised $4.0M · modeled $177.5M (est)CytoDel, INC. · Seed Raised $4.1M · modeled $173.4M (est)Finch Therapeutics, Inc. · Seed Raised $4.5M · modeled $165.8M (est)Cordex Systems, Inc · Seed Raised $6.4M · modeled $164.2M (est)Viking Therapeutics, Inc. · Seed Raised $3.7M · modeled $162.3M (est)Escalier Biosciences B.V. · Seed Raised $3.5M · modeled $155.4M (est)Corino Therapeutics, Inc. · Seed Raised $3.5M · modeled $154.3M (est)Captozyme Inc. · Seed Raised $3.4M · modeled $151.0M (est)BluDiagnostics, Inc. · Seed Raised $4.5M · modeled $151.0M (est)FORGE Life Science, LLC · Seed Raised $3.6M · modeled $149.5M (est)Magnesium Development Company, LLC (this company) Raised $2.5M · modeled $108.8M (est)Magnesium Development Company, LLC
CompanyStageRaised · realValue · estvs peer med.
Mimedx Group, Inc.Seed$8.2M$177.6M2.50×
Kenjockety Biotechnology, LLCSeed$4.0M$177.6M2.50×
Helocyte, Inc.Seed$4.0M$177.5M2.50×
CytoDel, INC.Seed$4.1M$173.4M2.44×
Finch Therapeutics, Inc.Seed$4.5M$165.8M2.33×
Cordex Systems, IncSeed$6.4M$164.2M2.31×
Viking Therapeutics, Inc.Seed$3.7M$162.3M2.28×
Escalier Biosciences B.V.Seed$3.5M$155.4M2.19×
Corino Therapeutics, Inc.Seed$3.5M$154.3M2.17×
Captozyme Inc.Seed$3.4M$151.0M2.12×
BluDiagnostics, Inc.Seed$4.5M$151.0M2.12×
FORGE Life Science, LLCSeed$3.6M$149.5M2.10×
Magnesium Development Company, LLC this companySeed$2.5M$108.8M1.53×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$1.0M2016-02-01$5.6M$55.2M85%
Seed$2.5M2017-09-08$12.3M$108.8M90%
Seed$1.8M2017-09-08$9.0M$79.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$1.0M2016-02-01
    • First recorded raise — entered as Pre-Seed.
    • 4 investors on this round.
  2. Seed$2.5M2017-09-08
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
    • 9 investors on this round.
  3. Seed$1.8M2017-09-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× smaller than the prior — bridge or down round.
    • 5 investors on this round.
Intelligence
2018 ~Q2
Modeled next raise · ~10mo cadence
$1.8M
Modeled next size est.range $1.8M$2.9M
0.7×
Last step-up
$1.5M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Michael DeVries7 other2017-09
Robert Ball6 other2017-09
Matthew Ahearn5 other2016-02
Donald Running4 other2016-02
Mike DeVries3 other2016-02
Rob Ball3 other2016-02
Jeff Ondrla1 other2016-02
Stephen LeBeau1 other2016-02
Matt Milanowksi2017-09
Mike Milanowksi2016-02
Registry & provenance

Magnesium Development Company, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1666465
SEC CIK
2014
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Orthopedic Driven Imaging, LLCBiotechnologySeed$3.5M$8.3Mnetwork1 shared operator · same sector · same stage
nanoMAG, LLCBiotechnologySeed$4.0M$126.9Mnetwork1 shared operator · same sector · same stage
Arthrotak, LLCBiotechnologySeed$1.5M$4.5Mnetwork1 shared operator · same sector · same stage
Genesis Innovation Group, LLCBiotechnologyPre-Seed$500K$5.5Mnetwork2 shared operators · same sector
CPD to SPD, LLCOtherSeries A$7.4M$8.1Mnetwork3 shared operators
Shoulder Innovations, LlcOther Health CarePre-Seed$794K$18.3Mnetwork3 shared operators
EndGenitor Technologies IncBiotechnologySeed$2.5M$108.8Msame sector · same stage
Pinnacle Transplant Technologies, LLCBiotechnologySeed$2.5M$108.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Magnus Medical, Inc.BiotechnologySeries C$153.8M86%
Memgen, Inc.BiotechnologySeries A$4.1M85%
Kit Company, Inc.BiotechnologySeed$119.8M85%
Mercury Bio, Inc.BiotechnologySeed$5.8M84%
Arsenal Biosciences, Inc.BiotechnologySeries D+$3.5B83%
MB Holdings 2025, Inc.BiotechnologySeries A$24.0M83%
Bolt Biotherapeutics, Inc.BiotechnologySeries C$433.3M83%
Ariel Precision Medicine, Inc.BiotechnologySeries A$190.5M83%
Frequently asked
How much funding has Magnesium Development Company, LLC raised?
Magnesium Development Company, LLC has raised approximately $2.5M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Magnesium Development Company, LLC's estimated valuation?
Provath's modeled valuation for Magnesium Development Company, LLC is approximately $108.8M (modeled range $1.8M–$853.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Magnesium Development Company, LLC at?
Magnesium Development Company, LLC's latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Sep 08.
What does Magnesium Development Company, LLC do and where is it based?
Magnesium Development Company, LLC operates in the Biotechnology sector, based in HOLLAND.
Explore related

See where Magnesium Development Company, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Magnesium Development Company, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.